Teriparatide
Teriparatide stimulates bone turnover, with a positive bone balance resulting in increased bone mass. Teriparatide is funded by the Pharmaceutical Benefits Scheme as an alternative treatment in patients who have a very high risk of fracture (bone mineral density T-score < –3), have experienced two or more fragility fractures and at least one symptomatic new fracture after 12 months of continuous therapy with an antiresorptive drug or are intolerant of antiresorptive drugs.